Technology in Parkinson's disease: Challenges and opportunities
ABSTRACT The miniaturization, sophistication, proliferation, and accessibility of technologies are enabling the capture of more and previously inaccessible phenomena in Parkinson's disease (PD). However, more information has not translated into a greater understanding of disease complexity to s...
Saved in:
| Published in | Movement disorders Vol. 31; no. 9; pp. 1272 - 1282 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Blackwell Publishing Ltd
01.09.2016
Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Summary: | ABSTRACT
The miniaturization, sophistication, proliferation, and accessibility of technologies are enabling the capture of more and previously inaccessible phenomena in Parkinson's disease (PD). However, more information has not translated into a greater understanding of disease complexity to satisfy diagnostic and therapeutic needs. Challenges include noncompatible technology platforms, the need for wide‐scale and long‐term deployment of sensor technology (among vulnerable elderly patients in particular), and the gap between the “big data” acquired with sensitive measurement technologies and their limited clinical application. Major opportunities could be realized if new technologies are developed as part of open‐source and/or open‐hardware platforms that enable multichannel data capture sensitive to the broad range of motor and nonmotor problems that characterize PD and are adaptable into self‐adjusting, individualized treatment delivery systems. The International Parkinson and Movement Disorders Society Task Force on Technology is entrusted to convene engineers, clinicians, researchers, and patients to promote the development of integrated measurement and closed‐loop therapeutic systems with high patient adherence that also serve to (1) encourage the adoption of clinico‐pathophysiologic phenotyping and early detection of critical disease milestones, (2) enhance the tailoring of symptomatic therapy, (3) improve subgroup targeting of patients for future testing of disease‐modifying treatments, and (4) identify objective biomarkers to improve the longitudinal tracking of impairments in clinical care and research. This article summarizes the work carried out by the task force toward identifying challenges and opportunities in the development of technologies with potential for improving the clinical management and the quality of life of individuals with PD. © 2016 International Parkinson and Movement Disorder Society |
|---|---|
| Bibliography: | ark:/67375/WNG-8PQWHS9T-B ArticleID:MDS26642 istex:014A11677B7C736F17A0D30BED2AAE676D8D2F78 The MDS Technology Task Force assembled a group of experts from the device and biopharmaceutical industry, clinical researchers, and engineers. The authors have taken every effort to minimize the influence of their home institutions and industries on the summarized outcome of the deliberations. A.J.E. has received grant support from Great Lakes Neurotechnologies. He serves as chair of the MDS Technology Task Force. P.B. is supported by the Michael J Fox Foundation, the National Institutes of Health, the National Science Foundation, and the Office of Naval Research. F.N. has received an educational grant from Medtronic Inc. W.M. has received grants from the European Union for FAIR‐PARK‐II, Moving beyond and SENSE‐PARK. J.M.D. is supported by the Davis Phinney Foundation to direct their Healthcare Strategy and Technology division. J.K. has received grant support Astrum IT and LicherMT and is chair of the task force “sensor‐based movement analysis” of the German Parkinson Society. B.M.E. has received grant support from Bosch Sensortec and Astrum IT and is co‐chair of the task force “sensor‐based movement analysis” of the German Parkinson Society. F.H. has research grants from Medtronic and has an equity/interest in APDM, a technology company. A.E.L. has served as an advisor for and received honoraria from Medtronic. R.R. is founding director and owner of the George‐Huntington‐Institute, a private research institute and QuantiMedis, a clinical research organization providing Q‐Motor (quantitative motor) services in clinical trials and research. J.G. is a full‐time employee of Great Lakes Neurotechnologies. M.H. has a financial interest in Global Kinetics Corporation, a company that manufactures and supplies the Parkinson's KinetiGraph (PKG), a wearable technology. M.A.L. has nothing to disclose. T.S. has received funding support for educational programming from GE Medical and Medtronic. E.R.D. has filed for a patent related to telemedicine and neurology and has received research funding from Great Lakes Neurotechnologies and Prana Biotechnology. K.K. directs data science and the partnership with Intel on wearable technologies and analytics enacted through the Michael J Fox Foundation for Parkinson's Research full time. G.M. is the founder and chief executive officer of Apptomics LLC. L.K. is a full‐time employee of Medtronic and serves as Board Observer at Functional Neuromodulation, Ltd. J.M.H. submitted a patent application on the use of body‐fixed sensors in Parkinson disease. The intellectual property rights for this patent application are held by the Tel Aviv Sourasky Medical Center. B.R.B. received research support from the Netherlands Organization for Scientific Research, the Michael J Fox Foundation, the Prinses Beatrix Foundation, the Stichting Parkinson Fonds, the National Parkinson Foundation, the Hersenstichting Nederland and the Parkinson Vereniging. S.P. is a full‐time employee of TEVA Pharmaceuticals. He serves as co‐chair of the MDS Technology Task Force. All other authors have no financial disclosure to report related to research covered in this article. Relevant conflicts of interests/financial disclosures ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Feature-3 content type line 23 ObjectType-Review-2 |
| ISSN: | 0885-3185 1531-8257 |
| DOI: | 10.1002/mds.26642 |